The Top 5 DE&I Stories in 2023
As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023.
Equity for Women in Healthcare: 131 Years is Too Long to Wait
Closing the gender gap in pharma—and how we get there together.
Q&A with Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk
Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.
Pharma's ESG Equation: Materiality and Strategy are Key
Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.
Tough—But Rewarding: The Evolution of the Chief Diversity Officer
What Smita Pillai, global chief diversity, equity, and inclusion (DE&I) officer, Regeneron, learned from two decades in DE&I roles.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.
